Baseline characteristics of participants according to CXCR4 mutational status
| Characteristic . | All participants (n = 45) . | CXCR4 WT (n = 28) . | CXCR4 MUT (n = 17) . | P value . |
|---|---|---|---|---|
| Age >65 y | 24 (53%) | 15 (54%) | 9 (53%) | .60 |
| Male sex | 30 (67%) | 19 (68%) | 11 (65%) | .54 |
| Hemoglobin level <115 g/L | 33 (73%) | 20 (71%) | 13 (76%) | .50 |
| Platelet count <100 × 109/L | 3 (7%) | 0 (0%) | 3 (18%) | .05 |
| Serum β2-microglobulin ≥3 mg/L | 28 (64%) | 20 (74%) | 8 (47%) | .11 |
| Serum IgM level ≥40 g/L | 26 (58%) | 14 (50%) | 12 (71%) | .22 |
| Serum IgM level ≥70 g/L | 6 (13%) | 3 (11%) | 3 (18%) | .66 |
| BM involvement ≥60% | 26 (58%) | 16 (57%) | 10 (59%) | .58 |
| Adenopathy ≥1.5 cm | 24 (53%) | 18 (64%) | 6 (35%) | .07 |
| Splenomegaly ≥15 cm | 12 (27%) | 10 (36%) | 2 (12%) | .08 |
| Acquired von Willebrand disease | 9 (20%) | 2 (7%) | 7 (41%) | .02 |
| Cryoglobulinemia | 3 (7%) | 2 (7%) | 1 (6%) | .67 |
| Low IPSSWM score | 9 (20%) | 3 (11%) | 6 (35%) | .06 |
| Intermediate IPSSWM score | 16 (36%) | 13 (48%) | 3 (18%) | |
| High IPSSWM score | 19 (43%) | 11 (40%) | 8 (47%) | |
| ≥12 mo from WM diagnosis | 18 (40%) | 11 (39%) | 7 (41%) | .57 |
| Characteristic . | All participants (n = 45) . | CXCR4 WT (n = 28) . | CXCR4 MUT (n = 17) . | P value . |
|---|---|---|---|---|
| Age >65 y | 24 (53%) | 15 (54%) | 9 (53%) | .60 |
| Male sex | 30 (67%) | 19 (68%) | 11 (65%) | .54 |
| Hemoglobin level <115 g/L | 33 (73%) | 20 (71%) | 13 (76%) | .50 |
| Platelet count <100 × 109/L | 3 (7%) | 0 (0%) | 3 (18%) | .05 |
| Serum β2-microglobulin ≥3 mg/L | 28 (64%) | 20 (74%) | 8 (47%) | .11 |
| Serum IgM level ≥40 g/L | 26 (58%) | 14 (50%) | 12 (71%) | .22 |
| Serum IgM level ≥70 g/L | 6 (13%) | 3 (11%) | 3 (18%) | .66 |
| BM involvement ≥60% | 26 (58%) | 16 (57%) | 10 (59%) | .58 |
| Adenopathy ≥1.5 cm | 24 (53%) | 18 (64%) | 6 (35%) | .07 |
| Splenomegaly ≥15 cm | 12 (27%) | 10 (36%) | 2 (12%) | .08 |
| Acquired von Willebrand disease | 9 (20%) | 2 (7%) | 7 (41%) | .02 |
| Cryoglobulinemia | 3 (7%) | 2 (7%) | 1 (6%) | .67 |
| Low IPSSWM score | 9 (20%) | 3 (11%) | 6 (35%) | .06 |
| Intermediate IPSSWM score | 16 (36%) | 13 (48%) | 3 (18%) | |
| High IPSSWM score | 19 (43%) | 11 (40%) | 8 (47%) | |
| ≥12 mo from WM diagnosis | 18 (40%) | 11 (39%) | 7 (41%) | .57 |
IPSSWM, International Prognostic Scoring System for WM; MUT, mutated; WT, wild-type.